Taken together, these data confirm the successful application of two different targeted agents, i.e. GSK126 and abemaciclib, in preclinical GBM models and provide further evidence for the potential of dual EZH2/CDK4/6 blockade to control this disease. The gene discussed is CDK4; the disease is glioblastoma.